Company Overview
About Altay Therapeutics
Altay Therapeutics is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $6.71 million raised including a $3 million seed round — developing first-in-class small molecule therapeutics that target transcription factors, historically considered "undruggable" proteins due to their lack of conventional binding sites, for rare genetic diseases and oncology indications. Founded in 2019, Altay's lead programs focus on facioscapulohumeral muscular dystrophy (FSHD) — a rare, progressive muscle disease affecting 1 in 8,500 people with no approved treatments — and cancer targets where transcription factor dysregulation drives tumor growth.
Business Model & Competitive Advantage
Altay's transcription factor inhibition platform addresses one of the fundamental challenges in drug discovery: transcription factors are proteins that regulate gene expression and are frequently mutated or overactivated in disease, but their flat, featureless binding surfaces have resisted conventional small molecule drug design for decades. Altay's approach uses proprietary computational modeling and medicinal chemistry to identify cryptic binding sites and design small molecules that disrupt protein-protein interactions or DNA binding of disease-relevant transcription factors. For FSHD specifically, the disease is driven by toxic expression of the DUX4 transcription factor — inhibiting DUX4 expression or activity represents the mechanistic target that Altay's lead compounds address.
Competitive Landscape 2025–2026
In 2025, Altay Therapeutics competes in the rare disease and oncology drug development market with Fulcrum Therapeutics (FSHD-focused, NASDAQ: FULC, losmapimod for FSHD), Arrowhead Pharmaceuticals (RNA interference for rare diseases), and transcription factor-focused startups for drug development funding and rare disease positioning. FSHD's unmet medical need (progressive muscle weakness, no approved treatment, large untreated patient population) creates orphan drug designation potential and expedited FDA review pathways. Y Combinator's W20 biotech backing connects Altay with the life sciences investor community for future Series A fundraising. The 2025 strategy focuses on completing lead optimization for the FSHD program, generating clinical candidate data package for IND application filing, and establishing partnerships with academic medical centers for natural history data access.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Altay Therapeutics is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Altay Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Altay Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Altay Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Altay Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →